IBIO-101

N/A

Report date: 2022/01/19 09:53:22

Base Information

Drug NameIBIO-101
Drug Alias NameRTX-003IBIO-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-IL2RA
TargetsInterleukin-2 receptor alpha chain
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRubryc Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesIbio IncRubryc Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A